Results 51 to 60 of about 182,230 (304)
Thrombocytopenia in the Neonate
Blood Reviews, 2008 Thrombocytopenia is one of the commonest haematological problems in neonates, affecting at least 25% of all admissions to neonatal intensive care units (NICUs) [Murray NA, Howarth LJ, McCloy MP et al. Platelet transfusion in the management of severe thrombocytopenia in neonatal intensive care unit patients. Transfus Med 2002;12:35-41; Garcia MG, Duenas
Roberts, I, Stanworth, S, Murray, N
openaire +3 more sources
Adverse effects of vaccinations against the Corona-virus SARS-CoV-2: insights and hindsights from a statistical perspective [PDF]
arXiv, 2022 Vaccinations against the virus SARS-CoV-2 have proven to be most effective against a severe corona disease. However, a significant minority of people is still critical of such a vaccination or even strictly reject it. One but surely not the only reason for this is the fear of undesired adverse effects.
arxiv
Immune Thrombocytopenia: A Rare Presentation of Pulmonary Sarcoidosis
European Journal of Case Reports in Internal Medicine, 2021 Thrombocytopenia may be the initial presentation of sarcoidosis, which is a systemic granulomatous disorder. Various pathophysiological mechanisms have been identified. Immune thrombocytopenia often has a severe presentation but may respond favourably to
Mariana da Silva Leal +5 more
doaj +1 more source
Hepatology, EarlyView., 2022 Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study. Abstract Background and Aims Alagille syndrome (ALGS) is a multisystem disorder, characterized by cholestasis. Existing outcome data are largely derived from tertiary centers, and real‐world data are lacking.
Shannon M. Vandriel +93 more
wiley +1 more source
ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib +16 more
wiley +1 more source
Serum bile acids as a prognostic biomarker in biliary atresia following Kasai portoenterostomy
Hepatology, EarlyView., 2022 Serum bile acid levels predict outcomes in patients with biliary atresia who achieve normalized bilirubin levels after Kasai portoenterostomy. Abstract Background and Aims In biliary atresia, serum bilirubin is commonly used to predict outcomes after Kasai portoenterostomy (KP).
Sanjiv Harpavat +22 more
wiley +1 more source
African Journal of Laboratory Medicine, 2020 Background: Thrombocytopenia is a common haematological disorder, characterised by platelet counts below 150 × 109/L. The aetiology of thrombocytopenia is multifactorial; notably, in a misdiagnosis this condition may be due to pre-analytical laboratory ...
Ayanda G. Jali, Bongani B. Nkambule
doaj +1 more source
Autoimmune thrombocytopenia [PDF]
Journal of Thrombosis and Haemostasis, 2005 Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder in which platelets coated with mainly antibodies against platelet GPIIb/IIIa and GPIb/IX are destroyed in the spleen. Recent evidence suggests that platelets are also destroyed by cytotoxic T cells. The diagnosis is made by exclusion for other causes of thrombocytopenia.
S.-J. Ho, Beng H. Chong
openaire +3 more sources
Advanced Science, EarlyView.This study uses gut microbiome data to predict corticosteroid response in patients with immune thrombocytopenia (ITP). Fecal samples from 212 patients with ITP are sequenced. Six machine‐learning algorithms are used to train predictive models. The support vector machine‐based model integrated clinical data and selected microbial species, diversities ...
Feng‐Qi Liu +38 more
wiley +1 more source
Hematological Oncology, Volume 40, Issue 5, Page 1020-1029, December 2022., 2022 Abstract In this subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285), we evaluated efficacy and safety of the anti‐CD38 monoclonal antibody isatuximab (Isa) in combination with carfilzomib‐dexamethasone (Isa‐Kd) versus Kd in older (≥70 years of age, n = 86) and younger (<70 years, n = 216) patients with relapsed multiple myeloma (MM).
Thierry Facon +15 more
wiley +1 more source